Disease · EFO_0008517
oral lichen planus
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. oral lichen planus. Diseases, record EFO_0008517. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008517
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs53
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| CLOBETASOL PROPIONATE | CHEMBL1159650 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 4 | Drugs and targets |
| TRIAMCINOLONE | CHEMBL1451 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 4 | Drugs and targets |
| CURCUMIN | CHEMBL140 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 4 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| PIMECROLIMUS | CHEMBL1200686 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 53
See all 53 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 15 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/240 | Drugs and targets |
| EPOR | Erythropoietin receptor | 1 | Erythropoietin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Early phase 1 | https://conductscience.org/library/genes/3269 | Drugs and targets |
| ITGAL | Integrin alpha-L/beta-2 (LFA-1) | 1 | Integrin alpha-L/beta-2 (LFA-1) inhibitor | Unknown | https://conductscience.org/library/genes/3683 | Drugs and targets |
| ITGB2 | Integrin alpha-L/beta-2 (LFA-1) | 1 | Integrin alpha-L/beta-2 (LFA-1) inhibitor | Unknown | https://conductscience.org/library/genes/3689 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials62
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02850601 | Dexamethasone Solution for the Treatment of Oral Lichen Planus | Phase 2 | 24 | 2021-05-14 | Lichen Planus | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT03509675 | Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. | Phase 2/3 | 23 | 2020-05-08 | Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction | IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00297037 | Pimecrolimus Cream for Oral Lichen Planus | Phase 2 | 21 | 2012-10-17 | Oral Lichen Planus | PIMECROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT00525421 | A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus | Phase 2 | 20 | 2013-08-07 | Oral Lichen Planus | CURCUMIN | Its record names the disease | ClinicalTrials.gov |
| NCT05973097 | Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy | Not applicable | 156 | Oral Lichen Planus | PAEONIFLORIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03592342 | Intra-oral Treatment of OLP With Rivelin®-CLO Patches | Phase 2 | 140 | Oral Lichen Planus | CLOBETASOL PROPIONATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04364555 | Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. | Phase 2/3 | 90 | Oral Lichen Planus | CLOBETASOL PROPIONATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00102557 | Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus | Phase 2 | 74 | Lichen Planus, Oral | CLOBETASOL, HYDROXYCHLOROQUINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00111072 | Dexamethasone to Treat Oral Lichen Planus | Phase 2 | 70 | Oral Lichen Planus | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02744378 | Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus | Phase 2 | 68 | Oral Lichen Planus | CLOBETASOL, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 62
See all 62 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active Ingredient vs Placebo: deaths from any cause | 0 of 23 | 0 of 23 | 46 | NCT03509675 | Trial comparisons |
| Active Ingredient vs Placebo: serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT03509675 | Trial comparisons |
| Dexamethasone Solution vs Dexamethasone Solution in Mucolox™: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT02850601 | Trial comparisons |
| Dexamethasone Solution vs Dexamethasone Solution in Mucolox™: serious adverse events | 1 of 12 | 0 of 12 | 24 | NCT02850601 | Trial comparisons |
| Pimecrolimus 1% Cream vs Vehicle Cream: serious adverse events | 0 of 10 | 0 of 11 | 21 | NCT00297037 | Trial comparisons |
| Curcuminoid vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT00525421 | Trial comparisons |
Papers from its trials15
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0008517
GET https://conductscience.org/api/diseases/v1/EFO_0008517/drugs?page=2